SecBot SecBot
8-K ·Filed Apr 24, 2026

SANA

Sana Biotechnology, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-174531
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No trading implications from this filing, it reflects a routine governance adjustment with no change in board composition or leadership. Monitor upcoming proxy filings for any additional board changes or governance updates.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.29
T+0 close · Apr 24, 2026 · via day close
Latest settled
−3.95%
T+60 · $3.16
Vs SPY
−9.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $3.29entry
  2. T+1 · 7mo ago −0.91%α −1.08% · $3.26
  3. T+5 · 7mo ago 0.00%α −0.91% · $3.29
  4. T+20 · 6mo ago −4.26%α −8.28% · $3.15
  5. T+60 · 4mo ago −3.95%α −9.03% · $3.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology reclassified director Steven D. Harr, M.D. from a Class I to a Class III director to balance board class composition in accordance with its charter. The move was administrative, with no interruption in service, and the board now has three directors in each class.

Key Facts

  • Steven D. Harr, M.D. resigned as a Class I director and was immediately reappointed as a Class III director.
  • The reclassification was made to achieve equal balance among the three board classes per the company's Certificate of Incorporation.
  • Dr. Harr's board service is deemed to have continued uninterrupted.
  • The board now consists of three directors in each of Class I, II, and III.

Financial Impact

No financial impact, this was an administrative board reclassification.

Risk Factors

  • None identified, this was a procedural board rebalancing with no executive departure or governance controversy.
  • Minimal investor relations risk given the clear explanation and continuity of service.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-174531
Document: 0001193125-26-174531-index-headers.html0001193125-26-174531
Document: 0001193125-26-174531-index.html0001193125-26-174531
Document: 0001193125-26-174531.txt0001193125-26-174531

Track record

12 reports on SANA

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Viewing Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026